Coya Therapeutics rises on positive data for Alzheimer's disease therapy

Coya Therapeutics

17/07/2023 13:14

** Shares of drug developer Coya Therapeutics Inc  COYA.O 
rise ~11% to $4.45 premarket
    ** Co reports additional positive data for its experimental
therapy to treat Alzheimer's disease (AD) 
    ** Says the therapy, COYA 301, administered as an
under-the-skin injection, significantly reduced
neuroinflammation in AD patients, according to data from a small
proof-of-concept study 
     ** COYA 301 belongs to a class of drugs called low-dose
IL-2, designed to enhance the function of immune response-
suppressing regulatory T cells
    ** Co expects to report top-line data from COYA 301's
ongoing mid-stage AD trial in July 2024  
    ** Up to last close, stock down ~15.4% YTD   

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))